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Abstract: Background
Regional anaesthesia is increasingly used in enhanced recovery programmes following
total hip replacement (THR) and total knee replacement (TKR). However debate
remains about its potential benefit over general anaesthesia given complications
following surgery are rare. We assessed the risk of complications in THR and TKR
patients receiving regional anaesthesia compared with general anaesthesia using the
world’s largest joint replacement registry.
 
Methods
We studied the National Joint Registry for England, Wales, Northern Ireland and the
Isle of Man linked to English hospital inpatient episodes for 779,491 patients
undergoing THR and TKR. Patients received either regional anaesthesia (n=544,620,
70%) or general anaesthesia (n=234,871, 30%). Outcomes assessed at 90 days
included length of stay, readmissions, and complications. Regression models were




Length of stay was reduced with regional anaesthesia compared with general
anaesthesia (THR=-0.49 days, 95% confidence interval (CI)=-0.51 to -0.47 days,
p<0.001; TKR=-0.47 days, CI=-0.49 to -0.45 days, p<0.001). Regional anaesthesia
also had a reduced risk of readmission (THR odds ratio (OR)=0.93, CI=0.90-0.96; TKA
OR=0.91, CI=0.89-0.93); any complication (THR OR=0.88, CI=0.85-0.91; TKA
OR=0.90, CI=0.87-0.93); urinary tract infection (THR OR=0.85, CI=0.77-0.94; TKR
OR=0.87, CI=0.79-0.96); and surgical site infection (THR OR=0.87, CI=0.80-0.95; TKR




Regional anaesthesia was associated with reduced length of stay, readmissions, and
complications following THR and TKR when compared with general anaesthesia. We
recommend regional anaesthesia should be considered the reference-standard for
patients undergoing THR and TKR.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Cover letter 
Submission type: New 
Manuscript category: Original article 
 
Title: Does regional anaesthesia reduce complications following total hip and knee 
replacement compared with general anaesthesia? An analysis from the National Joint 
Registry for England, Wales, Northern Ireland and the Isle of Man 
 
Authors: Gulraj S Matharu,1,2 Cesar Garriga,1,3 Amar Rangan,1,4,5 Andrew Judge1,2 
 
Institution: 
1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, 
University of Oxford, Nuffield Orthopaedic Centre, Oxford, OX3 7LD, United 
Kingdom. 
2. Musculoskeletal Research Unit, Department of Translational Health Sciences, University 
of Bristol, BS10 5NB, United Kingdom. 
3. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology 
and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, 
Windmill Road, Oxford, OX3 7LD, UK. 
4. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man 
5. Department of Health Sciences, University of York, Seebohm Rowntree Building, 
Heslington, York, YO10 5DD, United Kingdom. 
 
Cover letter
All of the aforementioned authors have actively participated in the study, and the work has 
not been submitted elsewhere for consideration for publication. 
 
IRB approval: With support under Section 251 of the NHS Act 2006, the Ethics and 
Confidentiality Committee (ECC), (now the Health Research Authority Confidentiality 
Advisory Group) allows the NJR to collect patient data where consent is indicated as ‘Not 
Recorded’. 
Consent for publication: Before Personal Data and Sensitive Personal Data is recorded, 
express written patient consent is provided. The NJR records patient consent as either ‘Yes’, 
‘No’, or ‘Not Recorded’. 
Availability of data and material: Access to data is available from the National Joint 
Registry for England and Wales, Northern Ireland and the Isle of Man, but restrictions apply 
to the availability of these data, which were used under license for the current study, and so 
are not publicly available. Data access applications can be made to the National Joint 
Registry Research Committee. Access to linked HES and PROMs data is available through 
data applications to NHS Digital. 
Competing interests: GSM has received personal fees for undertaking medicolegal work for 
Leigh Day. CG has no relevant conflicts of interest. AR holds non-commercial research 
grants from NIHR, ORUK & H2020; his department has received educational and research 
grants from DePuy Ltd. AJ has received consultancy fees from Freshfields Bruckhaus 
Deringer, and has held advisory board positions (which involved receipt of fees) from 
Anthera Pharmaceuticals, INC. 
Funding: This project was funded by the NIHR Health Services and Delivery Research 
programme (project number 14/46/02). AJ is supported by the NIHR Biomedical Research 
Centre at the University Hospitals Bristol NHS Foundation Trust and the University of 
Bristol. The views expressed in this publication are those of the authors and do not 
necessarily reflect those of the NHS, the National Institute for Health Research or the 
Department of Health and Social Care.  
Authors’ Contributions: All authors conceived and designed the study. GM, CG and AJ 
analysed the data. All authors interpreted data and wrote, edited and approved the final 
report. All authors agree to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. AJ is the guarantor for this study and had final responsibility for 
manuscript submission. 
 
13th January 2020 
Response to reviewer comments for Manuscript # JOA-D-19-01646 
"Does regional anaesthesia reduce complications following total hip and knee 
replacement compared with general anaesthesia? An analysis from the National Joint 
Registry for England, Wales, Northern Ireland and the Isle of Man" 
 
Many thanks for reviewing our work. We appreciate all the comments received and feel that 
these have helped improve our paper. All responses to the reviewer comments below are 
provided in bold text, and we have cited both page number and line number for any changes 




Reviewer #1: This is a retrospective analysis on a large population-based registry which 
intends to compare general vs regional anesthesia for joint replacement surgery in terms of 
multiple outcomes.  
No specific comments to address. 
 
The study is well designed since it addresses most of relevant outcomes and potential 
confounders. Furthermore, the decision to combine multiple databases in order to detect as 
many outcomes as possible is a great effort that adds valuable information. In addition, the 
manuscript is clear, well-written and organized thus making the paper very enjoyable to 
read.  
No specific comments to address. 
 
My only concern is in regards to the effect of the historic trend in the use of anesthetic 
techniques on the current results since the proportion of general anesthesia was greater during 
the first years of observation.  
 
Within the materials and methods section, authors state that the year of surgery was included 
for adjustment for the statistical analysis and then, in the discussion section, they 
acknowledge that the study can not exclude the possibility that the changes in practice are 
responsible for the differences found between anesthetic techniques. This topic deserves a 
more detailed description of the adjustment made during statistical analysis, further 
discussion and a modification in the conclusion statement, if needed. 
We thank the reviewer for this useful comment. In the analyses we had adjusted for 
year as a confounding variable in the multivariable regression models, with year as a 
binary variable (2008-12 versus 2013-17). To help address the reviewers comment, we 
have now conducted further analyses, using likelihood ratio tests to test for evidence of 
an interaction between anaesthetic techniques with year of surgery, for each of the 
study outcomes. We have now explained these extra details in our statistical analysis 
section of the revised manuscript (lines 156-7 and lines 154-6). These analyses allow us 
to address the question of whether the effect of regional anaesthesia on outcomes is the 
same in earlier versus later years of surgery. The results of the extra analyses have been 
presented (lines 248-269) and it has also been discussed further in the paper (lines 374-
8). 
 
In summary, very interesting paper, well written, and it contributes to currently available 
knowledge. Must be published if authors are able to explain the effect of that possible 
shortcoming.   




Reviewer #2: The authors performed a retrospective review of the large UK Registry to 
compare outcomes of TKR and THR performed under regional versus general anesthesia and 
found a statistically significant decrease in length of stay as well as certain complications. 
Overall, this is a well-written, relevant study that provides good evidence for the benefits of 
regional anesthesia.  I do have a few questions and issues that I would like the authors to 
address. 
Specific comments addressed in turn below 
 
TITLE AND ABSTRACT:  The nomenclature for the Registry that was studied is slightly 
confusing, at least to this non-European reviewer.  In Line 15, it is listed as the "UK National 
Joint Registry," yet from the title (as well as Lines 87-88) it would appear that Scotland is not 
included.  Also, Line 15 mentions "English hospital inpatient episodes": does the registry also 
include data from hospitals in Wales, Northern Ireland, etc.? 
We thank the reviewer for highlighting this point, and apologise for the confusion. The 
National Joint Registry is based on data from England, Wales, Northern Ireland and 
the Isle of Man. Therefore the title and the text in the methods is correct, but we have 
now corrected the abstract (line 15) to reflect this, given data from Scotland is not 
included in the NJR. Linkage to determine outcomes following joint replacement is only 
permitted with hospital inpatient episodes that occur in England via the Hospital 
Episode Statistics data, as linkage to the NJR is currently not available for the small 
proportion of joint replacements recorded in the NJR which are performed in Wales, 
Northern Ireland and the Isle of Man. 
 
INTRODUCTION: 
Lines 45-53:  The wording here, regarding the impetus for using joint replacement surgery as 
the impetus for "enhanced recovery" protocols, seems a bit awkward.  Perhaps replace "focus 
of enhanced recovery" with "main drivers of enhanced recovery protocols," and replace 
"active ingredients" with "components." 
These changes have now been made as suggested (line 51 and line 57). 
 
METHODS: 
Lines 115-6:  It is implied that the "regional anesthesia" all received a spinal, possibly with 
the addition of a peripheral nerve block.  Did any of the general anesthesia patients receive 
nerve blocks as well?  Is it possible to tease out whether or not adding a peripheral block 
provided any significant additional benefits to the patients in either group? 
Yes some of the general anaesthesia patients did receive a nerve block and we have 
adjusted the wording in the methods accordingly (line 122).  
 
We have conducted a sensitivity analysis re-running the analyses for all outcomes for: a) 
spinal only vs spinal + nerve block in just the spinal cohort, and then general only vs 
general + nerve block in just the general anaesthesia cohort. We have added this to the 
statistical analysis section (lines 166-8) and also included the results of this analysis 




Lines 161-8:  While it is reported that regional anesthesia decreased by approximately half a 
day (for both THR and TKR), the overall LOS of 4-5 days seems a bit long.  Did the length 
of stay decrease over time during the years that were studied?  And has the relative degree of 
reduction in LOS from using regional anesthesia changed over time? 
This is a European based healthcare system, and given how these are designed (relative 
to USA systems) the length of stay is generally longer in European based studies. 
Furthermore we are presenting a large nationwide sample which is thus representative 
of practice across the nation over a 10-year period. Mean length of stay decreased from 
6.1 days in 2008 to 3.5 days in 2017 for TKR and for THR from 6.3 days to 3.4 days. 
The decrease was consistent across both general and spinal groups, with LOS always 
lower for the regional group across all years of the study. We have now added this 
information to the results section (lines 188-192). 
 
Lines 182-9:  It is noted that regional anesthesia was associated with a decrease in overall 
complications, as well as a number of specific complications.  However, did regional 
anesthesia result in a change in the relative distribution of specific complications (or, at least, 
a difference in which complications were most common)?  Such a difference could also have 
implications for enhanced recovery protocols. 
Table 2 shows the relative distribution of the specific complications in each anaesthetic 
group for hips, and also for knees.  
 
In hips, the 5 commonest complications (in order) with regional anaesthesia were: 
anaemia, surgical site infection, respiratory tract infection, VTE, and urinary tract 
infection. 
In hips, the 5 commonest complications (in order) with general anaesthesia were: 
anaemia, surgical site infection, VTE, respiratory tract infection, and urinary tract 
infection. 
 
In knees, the 5 commonest complications (in order) with regional anaesthesia were: 
surgical site infection, anaemia, VTE, respiratory tract infection, and urinary tract 
infection. 
In knees, the 5 commonest complications (in order) with general anaesthesia were: 
surgical site infection, anaemia, VTE, respiratory tract infection, and urinary tract 
infection. 
 
Therefore, the relative distribution of the specific complications between regional and 
general anaesthetic groups was similar following both THR and TKR (Table 2). We 
have added such a statement to the Results to highlight this (lines 220-1). 
 
 
Finally, while the use of the word "secular" in Lines 212 and 261 is technically correct (in the 
"economic" sense), it may be confusing to some readers who associate the term with its "non-
religious" definition.  Perhaps use "steady" or "persistent" instead. 
These changes have now been made as suggested (lines 243, 245, and 344).  
 
Reviewer #3:  The authors have submitted a nice paper.  A few questions/concerns: 
 
1. I recommend eliminating the comment about the “world’s largest joint registry” (line 
12).  The AJRR now contains more patient records (over 1.5 million) thus making it the 
largest national registry in the world. 
As stated in the methods of the initial paper the NJR “..contains over 2 million primary 
THR and TKR procedures..”. This can be confirmed on their website and in the latest 
16th annual report on page 36, Figure 3.1, which confirms there are 2,293,452 primary 
THRs and TKRs combined which are recorded within the registry (available at: 
https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2016th%20Annual%2
0Report%202019.pdf). Data from the Australian joint Registry suggests 1,492,892 such 
procedures have been performed 
(https://aoanjrr.sahmri.com/documents/10180/668596/Lay+Summary+of+Hip+and+Kn
ee+Replacement/9a0ce4fc-c157-0c7f-8850-a43027d2e044). Therefore we have left in the 
statement about the NJR being the worlds largest joint registry as we believe it is still 
valid. 
 
2. Why is “smoking” listed as a key word (lines 38-39)? 
We apologise for this mistake and have removed this key word. 
 
3. For the exposure section (lines 114-117) the authors report the overall breakdown of 
general versus regional (30/70). How does that breakdown for THA vs TKA?  I would think 
the percentage of patients receiving general alone is higher for THA compared to 
TKA.  Please include this breakdown. 
This breakdown was included in the first row of Table 1. For THA the split is 30.2% 
general vs. 69.8% regional. For TKA the split is 30.1% general vs. 69.9% regional. 
Therefore the split between anaesthetic types is almost identical between THA and 
TKA. For clarity we have added a sentence in the Methods to highlight the split by joint 
type (lines 122-4). 
 
4. Please clarify the categories.  Would a patient with general anesthesia and a nerve 
block fall into the “general” cohort?  Line 114-117 suggests that the two categories are really 
spinal versus general anesthesia and the presence of nerve block does not matter (i.e. the only 
requirement to be in the regional category is presence of spinal).  If I am correct, than isn’t 
the category “regional” misleading as many patients who received a nerve block (which is a 
regional anesthesia technique) would end up in the general category?  Please clarify. 
We have now clarified the definition of the exposure group in the Methods in response 
to this and a previous reviewer comment (lines 121-2). The further analyses performed 
(see response to comment 5 below) confirmed that very few patients were in the general 
anaesthetic + nerve block group (4.5% for THR and 7.5% for TKR). Furthermore, 
although nerve block as a regional technique, they still had a general anaesthetic which 
is the main type of anaesthesia they received so we feel they cannot be classed as 
completely having “regional” anaesthesia. Therefore we consider it is still appropriate 
to keep the terminology of the exposure group as general vs. regional anaesthesia, and 
in addition our subanalysis below and in the revised manuscript highlights the effect of 
addition of a nerve block to both general and spinal alone, which helps clarify this issue. 
 
5. Do the authors have the numbers available to compare multiple groups (spinal alone, 
spinal + nerve block, general alone, general + nerve block)?  Breaking this into two 
categories seems to be an over simplification. 
We have now performed this additional work as a sensitivity analysis in response to this 
and a previous reviewer comment (line 122 and 166-8 in the Methods, lines 271-80 in 
the Results, lines 327-342 in the Discussion, and Appendix 3). Please see also our specific 
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 1 
Does regional anaesthesia reduce complications following total hip and knee 1 
replacement compared with general anaesthesia? An analysis from the National Joint 2 





Regional anaesthesia is increasingly used in enhanced recovery programmes following total 8 
hip replacement (THR) and total knee replacement (TKR). However debate remains about its 9 
potential benefit over general anaesthesia given complications following surgery are rare. We 10 
assessed the risk of complications in THR and TKR patients receiving regional anaesthesia 11 
compared with general anaesthesia using the world’s largest joint replacement registry. 12 
 13 
Methods 14 
We studied the National Joint Registry for England, Wales, Northern Ireland and the Isle of 15 
Man linked to English hospital inpatient episodes for 779,491 patients undergoing THR and 16 
TKR. Patients received either regional anaesthesia (n=544,620, 70%) or general anaesthesia 17 
(n=234,871, 30%). Outcomes assessed at 90 days included length of stay, readmissions, and 18 
complications. Regression models were adjusted for patient and surgical factors to determine 19 
the effect of anaesthesia on outcomes. 20 
 21 
Results 22 
Length of stay was reduced with regional anaesthesia compared with general anaesthesia 23 
(THR=-0.49 days, 95% confidence interval (CI)=-0.51 to -0.47 days, p<0.001; TKR=-0.47 24 
days, CI=-0.49 to -0.45 days, p<0.001). Regional anaesthesia also had a reduced risk of 25 
Manuscript (No Author Info./INCLUDE Title & Abstract/NUMBER
ALL LINES)
Click here to view linked References
 2 
readmission (THR odds ratio (OR)=0.93, CI=0.90-0.96; TKA OR=0.91, CI=0.89-0.93); any 26 
complication (THR OR=0.88, CI=0.85-0.91; TKA OR=0.90, CI=0.87-0.93); urinary tract 27 
infection (THR OR=0.85, CI=0.77-0.94; TKR OR=0.87, CI=0.79-0.96); and surgical site 28 
infection (THR OR=0.87, CI=0.80-0.95; TKR OR=0.84, CI=0.78-0.89). Anaesthesia type did 29 
not affect the risk of revision surgery or mortality. 30 
 31 
Conclusions 32 
Regional anaesthesia was associated with reduced length of stay, readmissions, and 33 
complications following THR and TKR when compared with general anaesthesia. We 34 
recommend regional anaesthesia should be considered the reference-standard for patients 35 
undergoing THR and TKR. 36 
 37 
Key words 38 





Total hip replacement (THR) and total knee replacement (TKR) are commonly performed 43 
and effective interventions for treating arthritis.[1] Predictions suggest that the number of 44 
these procedures will continue to increase worldwide.[2, 3] Being high volume elective 45 
surgical procedures, THR and TKR lend themselves well to standardising best practice for 46 
improving patient outcomes, and were the main drivers of enhanced recovery protocols in 47 
musculoskeletal care. Through a Department of Health led programme an “enhanced 48 
recovery” patient pathway for THR and TKR was introduced across all English hospitals 49 
from 2009.[4, 5]. Enhanced recovery is a complex intervention that focuses on quality 50 
improvement in key areas of the patient care pathway – this includes changes that can reduce 51 
the risk of complications and speed up patients’ recovery time. There is a need for clarity on 52 
its core components, and how they are exerting their effect.[6, 7]. 53 
 54 
Both THR and TKR can be performed under either general anaesthesia or regional 55 
anaesthesia, however there is uncertainty about which method of anaesthesia leads to better 56 
outcomes.[8] The advent of enhanced recovery has led to an increase in the use of regional 57 
anaesthesia for THR and TKR.[9, 10] A systematic review of 29 studies involving 10,488 58 
patients undergoing THR or TKR showed that regional anaesthesia was associated with a 59 
lower length of stay compared with general anaesthesia; however both techniques were 60 
equally effective with a similar risk of adverse events.[11] The authors concluded that there 61 
was limited evidence to suggest that regional anaesthesia was associated with better 62 
perioperative outcomes. By contrast, observational studies have suggested advantages of 63 
regional anaesthesia over general anesthesia following THR and TKR in terms of mortality, 64 
complications, and blood loss, in addition to length of stay.[12-15] 65 
 66 
 4 
The absolute risk of complications following THR and TKR is rare,[16] therefore randomised 67 
controlled trials comparing anesthetic types would need very large numbers for assessing 68 
serious adverse events such as mortality and cardiorespiratory complications, and may not be 69 
feasible. Observational studies have been criticised given these involved relatively small 70 
cohorts (under 20,000 patients); they are limited by the information available; do not report 71 
relevant outcomes, particularly patient reported outcomes;[11] and some only report 72 
morbidity during the hospital admission, thus not capturing post-discharge events.[12] There 73 
is therefore the need to examine the effects of regional anaesthesia over general anaesthesia 74 
in terms of morbidity and mortality following THR and TKR in a large patient cohort with 75 
sufficiently granular data, in order to overcome these limitations.  76 
 77 
The study aim was to assess the risk of complications following THR and TKR in patients 78 
receiving regional anaesthesia compared with general anaesthesia using data from the world’s 79 
largest mandated national arthroplasty registry. We also assessed temporal trends in 80 





Study design and data source 85 
A retrospective analysis of prospectively collected observational data was performed using 86 
data from the National Joint Registry (NJR) for England, Wales, Northern Ireland and the 87 
Isle of Man. Data capture commenced in April 2003 and contains over 2 million primary 88 
THR and TKR procedures, capturing approximately 95% of all such procedures.[16] Patients 89 
consent for their details to be recorded within the NJR and data linkage to be performed, with 90 
92% providing consent.[16] Operating teams complete data capture forms after performing 91 
THR and TKR, which are entered onto the NJR database. Independent validation studies 92 
have reported that data completion and accuracy are excellent for procedures within the 93 
NJR.[17, 18]  94 
 95 
Primary operations from the NJR were subsequently linked with Hospital Episode Statistics 96 
(HES) data, which contains records of all hospital inpatient episodes undertaken in National 97 
Health Service trusts in England (125 million each year). HES uses International 98 
Classification of Diseases 10th revision (ICD-10) to record diagnoses and the Office of 99 
Population Censuses and Surveys version 4 (OPCS-4) procedures to record diseases, 100 
complications, interventions and procedures from secondary care (Appendix 1). The NJR 101 
dataset was also linked with the Office for National Statistics (ONS) database, which 102 
provides data on all-cause mortality. 103 
 104 
Exclusion criteria 105 
All patients undergoing primary THR or TKR for osteoarthritis recorded in the NJR were 106 
eligible for inclusion up until February 2017. Exclusions were made as follows: (1) patients 107 
 6 
with metal-on-metal THR bearings, or partial knee replacements; (2) received anaesthesia not 108 
defined by the exposure group (below); (3) procedure performed as an emergency; and (4) no 109 
linkage to HES data (i.e. surgery prior to 2008). There were 779,491 patients included for 110 
analysis (Figure 1). 111 
 112 
Exposure 113 
The NJR collects data on the type of anaesthesia used for each procedure. Patients were 114 
grouped as having either regional anaesthesia (spinal anaesthesia +/- sedation +/- nerve 115 
block: n=544,620, 70%) or general anaesthesia (+/- nerve block: n=234,871, 30%). The 116 
proportion receiving each anaesthesia type was similar for THA (69.8% regional vs. 30.2% 117 
general) and TKA (69.9% regional vs. 30.1% general). These groups were chosen to reflect 118 
enhanced recovery protocols compared with standard anaesthesia techniques. 119 
 120 
Covariates 121 
For each procedure data were available on patient demographics and the type of surgery. This 122 
included age, sex, body mass index (BMI), area-level deprivation using the index of multiple 123 
deprivation (IMD: based on patient residential postcode and rural/urban indicator),[19] 124 
American Society of Anesthesiologists (ASA) grade,[20] Charlson comorbidity score,[21] 125 
unit type (public or private), mechanical and chemical venous thromboembolism (VTE) 126 
prophylaxis, surgeon grade, surgical approach (including whether minimally invasive 127 
technique), and components implanted (fixation, use of bone graft, and for THRs information 128 




Outcomes of interest were length of stay, and complications within 90 days of surgery, which 132 
is consistent with the recommended period for reporting morbidity following these 133 
procedures.[16, 22-24] The latter included readmission, revision surgery (removal, exchange, 134 
or addition of an implant), re-operations (excluding revision), and mortality, in addition to 135 
specific complications like stroke, infection (chest, urine, and surgical site), wound 136 
disruption, myocardial infarction, VTE, acute renal failure, blood transfusion, major 137 
haemorrhage (intracranial and gastrointestinal), and anaemia. Validated generic and joint 138 
specific patient reported outcome measures (PROMs) (preoperative and at 6 months 139 
postoperatively) were also assessed. These included the EQ5D,[25] the Oxford Hip Score 140 
(OHS) and the Oxford Knee Score (OKS).[26-28] The Oxford Scores are both scored from 0 141 
(worst) to 48 (best), whilst a score of 1 is the best outcome with the EQ5D. 142 
 143 
Statistical analysis 144 
The effect of anaesthesia type on outcomes following surgery was assessed using linear 145 
regression (for length of stay, EQ5D, OHS and OKS) and logistic regression (for 146 
complications). Analyses were performed separately for THRs and TKRs. For each outcome, 147 
models were adjusted for all patient and surgical factors, apart from BMI, given BMI is 148 
frequently missing in the NJR.[16] Patient and surgical factors adjusted for were age, sex, 149 
ASA grade, Charlson grade, year of primary surgery (as a binary variable: 2008-2012 versus 150 
2013-2017), unit type, deprivation status, chemical and mechanical VTE prophylaxis, 151 
surgeon grade, surgical approach, minimally invasive surgery, and implant fixation. In the 152 
THR analyses, adjustment was also made for bearing material and femoral head size. Models 153 
predicting the postoperative EQ5D, OHS, and OKS were also adjusted for the respective 154 
preoperative score.  155 
 156 
 8 
We performed the following sensitivity analyses: (1) regression models were adjusted for all 157 
patient and surgical factors, including BMI; (2) tested for evidence of an interaction between 158 
year of surgery and type of anaesthesia on outcomes using a likelihood ratio test; (3) assessed 159 
outcomes in (a) general anaesthesia only vs. general anaesthesia with a nerve block, and in 160 
(b) spinal anaesthesia only vs. spinal anaesthesia with a nerve block. All statistical analyses 161 
were performed with Stata (version 14.2). 162 
 9 
Results 163 
Of 779,491 patients studied, 353,387 underwent THR and 426,104 underwent TKR (Table 164 
1).  165 
 166 
Length of stay 167 
Following THR, mean (standard deviation) length of stay after regional anaesthesia was 4.6 168 
days (3.4 days) compared with 5.2 days (4.0 days) following general anaesthesia (Table 2). 169 
Following TKR, mean (standard deviation) length of stay after regional anaesthesia was 4.7 170 
days (3.5 days) compared with 5.2 days (3.9 days) following general anaesthesia. Regional 171 
anaesthesia was associated with a significantly reduced length of stay compared with general 172 
anaesthesia following THR (coefficient = -0.49 days, 95% confidence interval (CI)=-0.51 to -173 
0.47 days, p<0.001) and following TKR (coefficient = -0.47 days, CI= -0.49 to -0.45 days, 174 
p<0.001) (Table 3). 175 
 176 
For the whole cohort, the length of stay decreased between 2008 to 2017: for THR mean 6.3 177 
days to 3.4 days, and for TKR mean 6.1 days to 3.5 days. This decrease in length of stay over 178 
time was consistent across both the anaesthesia groups. However length of stay was always 179 
lower for the regional anaesthesia group compared with general anaesthesia for every 180 
calendar year from 2008 to 2017. 181 
 182 
General complications 183 
In both THR and TKR patients, regional anaesthesia was associated with a significantly 184 
reduced risk of readmission (THR odds ratio (OR)=0.93, CI=0.90-0.96; TKR OR=0.91, 185 
CI=0.89-0.93) and any complication (THR OR=0.88, CI=0.85-0.91; TKR OR=0.90, 186 
CI=0.87-0.93). In TKR only, regional anaesthesia was associated with a reduced risk of 187 
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reoperation compared with general anaesthesia (OR=0.79, CI=0.68-0.92, p=0.002). In both 188 
THR and TKR patients, the risk of revision surgery or mortality was not related to 189 
anaesthesia type (Table 3). 190 
 191 
Specific complications 192 
In THR patients, compared with general anaesthesia, regional anaesthesia was associated 193 
with a significantly reduced risk of the following: any VTE (OR=0.85, CI=0.77-0.93, 194 
p=0.001), pulmonary embolism (OR=0.77, CI=0.67-0.88, p<0.001), urinary tract infection 195 
(OR=0.85, CI=0.77-0.94, p=0.003), surgical site infection (OR=0.87, CI=0.80-0.95, 196 
p=0.001), acute renal failure (OR=0.78, CI=0.68-0.89, p<0.001), blood transfusion 197 
(OR=0.62, CI=0.48-0.80, p<0.001), and anaemia (OR=0.85, CI=0.79-0.92, p<0.001). There 198 
was no difference in the risk of all other complications between anaesthesia groups in THRs, 199 
including chest infection (Table 3). 200 
 201 
In TKR patients, compared with general anaesthesia, regional anaesthesia was associated 202 
with a significantly reduced risk of the following: urinary tract infection (OR=0.87, CI=0.79-203 
0.96, p=0.007), surgical site infection (OR=0.84, CI=0.78-0.89, p<0.001), and anaemia 204 
(OR=0.89, CI=0.83-0.95, p=0.001). There was no difference in the risk of all other 205 
complications between anaesthetic groups in TKRs, including chest infection, VTE, acute 206 
renal failure, and blood transfusion (Table 3). 207 
 208 
The relative distribution of the specific complications between regional and general 209 





Postoperative EQ5D scores were significantly higher in patients having regional anaesthesia 214 
compared with general anaesthesia (THR coefficient=0.021, CI=0.018-0.023, p<0.001 and 215 
TKR coefficient=0.019, CI=0.017-0.022, p<0.001). Postoperative OHS and OKS were 216 
significantly higher in patients having regional anaesthesia compared with general 217 
anaesthesia (THR coefficient=0.79, CI=0.70-0.88, p<0.001 and TKR coefficient=0.80, 218 
CI=0.71-0.88, p<0.001). None of the differences observed in postoperative PROMs reached 219 
clinical significance (OHS=5 points; OKS=4 points).[26, 29] 220 
 221 
All regression models were repeated for the sensitivity analysis, which produced similar 222 
findings to those of the main analysis (Appendix 2). 223 
 224 
Temporal Trends in anaesthesia use 225 
Overall the proportion of patients receiving regional anaesthesia was 69.8% in THR and 226 
69.9% in TKR. From 2008 to 2016 there has been a steady increase in the use of regional 227 
anaesthesia following both THR (from 57.1% to 76.8%) (Figure 2) and TKR (from 57.2% to 228 
77.8%). This change was associated with a concomitant steady decline in the use of general 229 
anaesthesia. 230 
 231 
Sensitivity analysis: Variation of anaesthesia use over time 232 
Given the variation of anaesthesia use over time, we also examined for interactions between 233 
year of surgery and type of anaesthesia on outcomes. This analysis would establish whether 234 




For THR, the only evidence of a significant interaction with year of surgery was for surgical 238 
site infection (p=0.0292). Stratified analyses showed there was only an effect of regional 239 
anaesthesia reducing the risk of surgical site infection for the later years (2013-17) compared 240 
with earlier years (OR=0.80, CI=0.17-0.90, p<0.001). 241 
 242 
For TKR, there was evidence of interactions with year of surgery for the following outcomes: 243 
readmission (p=0.0016), respiratory tract infection (p=0.0074), major haemorrhage 244 
(p=0.0245) and anaemia (p=0.0034). For readmission, the effect of regional anaesthetic was 245 
weaker in 2008-12 (OR=0.94, CI=0.91-0.96, p<0.001), compared to 2013-17 (OR=0.88, 246 
CI=0.86-0.91, p<0.001). There was only evidence of a significant effect in later years (i.e. 247 
2013-17) for major haemorrhage (OR=0.70, CI=0.55-0.90, p=0.004) and anaemia (OR=0.79, 248 
CI= 0.72-0.88, p<0.001). There was an increased risk of respiratory tract infection for 249 
regional anaesthesia but only in 2008-12 (OR=1.20, CI=1.04-1.37, p=0.011). 250 
 251 
Sensitivity analysis: Addition of a nerve block 252 
Compared to general anaesthesia only, the addition of a nerve block had a reduced risk of 253 
readmission in both THR (OR=0.92, CI=0.87-0.97, p=0.004) and TKR (OR=0.95, CI=0.92-254 
0.99, p=0.013) (Appendix 3). In TKR only, general anaesthesia with a nerve block was also 255 
associated with a reduced risk of surgical site infection (OR=0.80, CI=0.70-0.90, p<0.001) 256 
and improved EQ5D score though the later did not reach clinical significance (Appendix 3).  257 
 258 
Compared to spinal anaesthesia only, the addition of a nerve block was associated with an 259 
increased length of stay for TKR only, though this may not reach clinical significance  260 




This is the largest study assessing the risk of complications following THR and TKR in 264 
patients receiving regional anaesthesia compared with general anaesthesia. We observed that 265 
regional anaesthesia was associated with a reduced length of stay, and a reduced risk of 266 
readmissions and complications following THR and TKR when compared with general 267 
anaesthesia. 268 
 269 
Regional anaesthesia was associated with a reduced length of stay (approximately half a day) 270 
compared with general anaesthesia following both THR and TKR. This is consistent with the 271 
findings of a systematic review of 29 studies, which reported the overall reduction in length 272 
of stay observed with regional anaesthesia was 0.40 days.[11] Furthermore a large cohort 273 
study reported fewer patients receiving regional anaesthesia had a prolonged length of stay 274 
(above 75th percentile) compared with general anaesthesia.[12] Given that over 200,000 joint 275 
replacements are recorded annually on the NJR[16] and the significant costs associated with 276 
hospital admissions,[30] the decrease in length of stay alone which was associated with 277 
regional anaesthesia has the potential for substantial healthcare savings.  278 
 279 
The reduced risk of readmissions and complications following THR and TKR that we 280 
observed with regional anaesthesia would also provide further healthcare savings as noted 281 
previously,[12] in addition to the obvious benefits of reduced patient morbidity. A systematic 282 
review reported no difference between the risk of complications when using regional or 283 
general anaesthesia.[11] However this review included 19 trials, which means the power to 284 
detect differences in relatively rare secondary outcomes was low. Observational studies have 285 
shown regional anaesthesia has been associated with a lower risk of complications, including 286 
surgical site infection, blood transfusion, and VTE[12-15] We found similar results with 287 
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regional anaesthesia reducing the risk of surgical site infection, urinary tract infection, and 288 
anaemia in both THR and TKR patients, and reducing the risk of VTE, acute renal failure, 289 
and blood transfusion in THR patients only. Although it is acknowledged that the absolute 290 
risk of complications in each anaesthetic group were low (Table 2) and the difference in these 291 
risks between the anaesthetic groups were also low, these are important findings as many of 292 
these complications have substantial burdens for the patient and healthcare systems. For 293 
example surgical site infection, which is nationally reported in England[31] and very costly 294 
to treat (medical treatment alone per case is £3,696 / $4,657).[30] Some of the differences in 295 
complication risk between THR and TKR we observed are likely to reflect how the 296 
procedures are performed, for example with blood transfusion given TKR is performed with 297 
a tourniquet so there is less blood loss compared with THR. 298 
 299 
We did not find that regional anaesthesia reduced mortality, which is consistent with the 300 
findings from a recent systematic review.[15] Although some studies have observed the 301 
contrary,[12, 32] it has recently been shown that any potential effect of anaesthesia on 302 
mortality wanes with time.[33] We observed no clinically significant differences in generic 303 
and joint specific PROMs between anaesthesia types, therefore suggesting that patients gain 304 
no clinically meaningful benefit in these domains in relation to anaesthetic at six-months 305 
postoperatively. 306 
 307 
In more recent years nerve blocks have been frequently used as an adjunct anaesthesia 308 
technique in patients receiving THR and TKR. However currently there is still a lack of 309 
evidence to establish whether nerve blocks provide any clinical benefit over not 310 
administering one [34]. Our sensitivity analysis assessing the addition of a nerve block with 311 
spinal anaesthesia suggested that with the outcomes available for assessment there was no 312 
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significant clinical benefit of having a nerve block (compared with not having one); however 313 
there was a suggestion that nerve blocks were associated with an increased length of stay for 314 
TKR patients. Following general anaesthesia, the addition of a nerve block reduced the risk 315 
of readmission following both THR and TKR, and reduced the risk of surgical site infection 316 
following TKR. On the basis of our data, nerve blocks may be beneficial in patients 317 
undergoing general anaesthesia, but they may not provide any additional benefit in patients 318 
undergoing spinal anaesthesia. It is therefore recommended that further studies assess the 319 
benefit of adding a nerve block to both general anaesthesia and spinal anaesthesia in THR 320 
and TKR patients, which specifically assess early postoperative pain scores and other 321 
relevant outcome measures. 322 
 323 
There has been a steady increase in regional anaesthesia use for joint replacement since 2008, 324 
with 77% of patients now receiving regional anaesthesia. These observations were identical 325 
in the hip and knee cohorts, and likely reflect changes in clinical practice during this time. 326 
Between 2009 and 2011 the Department of Health in England introduced the Enhanced 327 
Recovery Partnership Programme, which promotes the use of regional anaesthesia.[5] More 328 
recently there have been attempts to perform THR and TKR as daycase surgery, with 329 
regional anaesthesia used in these cases in a number of countries given it is considered an 330 
important factor in reducing hospital stay and morbidity.[35] Our observations support the 331 
notion that regional anaesthesia has a number of advantages for patients undergoing THR and 332 
TKR in terms of length of stay, readmissions and complications. Given these findings, we 333 
recommend that all anaesthetists involved in joint replacement surgery should be capable of 334 
performing regional anaesthesia, as it is recognised to be more technically demanding and 335 
time consuming than general anaesthesia which has contributed to some of the resistance for 336 
using regional anaesthesia in certain regions.[12, 36] 337 
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 338 
Using a nationwide cohort from the world’s largest joint replacement registry helps increase 339 
the external validity and generalisibility of our findings. However this study has recognised 340 
limitations. Using observational data means causality cannot be inferred. Registry data does 341 
not include information regarding why the anaesthetic method was selected (regional versus 342 
general), the specific anaesthetic administered (technique, drugs, dose etc), the specific 343 
perioperative protocols used (including enhanced recovery), and the discharge destination. 344 
Although we have adjusted our data for numerous patient and surgical factors, it is 345 
recognised these factors, and other important variables not recorded in routinely collected 346 
datasets (e.g. the need for invasive intraoperative monitoring), may influence our findings 347 
with respect to the differences in complications and length of stay between the two 348 
anaesthetic groups. In addition, although we have adjusted for numerous important patient 349 
and surgical factors, using observational data means we cannot definitively exclude that 350 
changes in surgical practice over time were responsible for the better findings in the regional 351 
anesthesia group, rather than the effect of the anaesthesia technique itself. However we did 352 
perform sensitivity analyses assessing for interactions between year of surgery and type of 353 
anaesthesia on outcomes, which supported our main findings and suggested that some of the 354 
findings in favour of using regional anaesthesia were only significant in more recent years 355 
(2013-17) so were a reflection of modern clinical practice. Missing BMI data is a limitation 356 
of NJR based studies.[22, 37, 38] We observed that the BMI distribution was balanced 357 
between the anaesthesia groups, and analysis of the subgroup of patients with BMI data 358 
available did not alter the findings from the regression models (Appendix 2). Although 359 
PROMs were available at 6 months, it is recognised that we had no early patient reported 360 
outcomes available regarding pain and nausea like those collected in trials.[8, 10] Finally, we 361 
had to exclude a number of cases from the NJR without HES data linkage (prior to 2008), 362 
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Regional anaesthesia was associated with a reduced length of stay, and a reduced risk of 367 
readmissions and complications following THR and TKR when compared with general 368 
anaesthesia. We recommend that regional anaesthesia should be considered the reference-369 
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Figure 1 Study selection criteria 
THR = total hip replacement; TKR = total knee replacement 
 
Figure 2 Temporal trends in anaesthesia use following total hip replacement  
Almost identical findings seen following total knee replacement. 
 























































Year of primary surgery
General Regional
Anaesthetic variation with year of primary total hip replacement
Figure 2 Click here to access/download;Figures (Number each one);Figure 2 Temporal
trends.eps
 
Table 1 Patient and surgical factors in primary total hip and knee replacement 
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VTE – mechanical 



















Surgeon grade        
Tables 1-3
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ASA = American Society of Anesthesiologists; BMI = body mass index; CoC = ceramic-on-ceramic; CoP = 
ceramic-on-polyethylene; LMWH = low molecular weight heparin; MoP = metal-on-polyethylene; NHS = 
 
National Health Service; NA = not applicable; SD = standard deviation; THR = total hip replacement; TKR = 
total knee replacement; VTE = venous thromboembolism. 
Values in brackets are percentages unless otherwise indicated.  
* Missing BMI data for 96,777 hips and 119,760 knees 
 
 
Table 2 Outcomes after primary total hip and knee replacement by anaesthetic type 









































































Revision at 90 days 1,355 (0.38) 438 (0.41) 917 (0.37)  387 (0.09) 111 (0.09) 276 (0.09) 
Reoperations within 














Mortality at 90 days 1,038 (0.29) 312 (0.29) 726 (0.29)  679 (0.16) 190 (0.15) 489 (0.16) 
Specific 
complications 
within 90 days 
       
VTE (DVT &/or PE) 2,043 (0.58) 718 (0.67) 1,325 (0.54)  2,757 (0.65) 871 (0.68) 1,886 (0.63) 
DVT only 1,102 (0.31) 380 (0.36) 722 (0.29)  1,449 (0.34) 459 (0.36) 990 (0.33) 
PE only 1,001 (0.28) 360 (0.34) 641 (0.26)  1,396 (0.33) 444 (0.35) 952 (0.32) 
Urinary tract 
infection 
1,712 (0.48) 544 (0.51) 1,168 (0.47)  1,902 (0.45) 580 (0.45) 1,322 (0.44) 
Surgical site 
infection 
2,639 (0.75) 886 (0.83) 1,753 (0.71)  4,378 (1.0) 1,503 (1.2) 2,875 (0.96) 
Acute renal failure 1,063 (0.30) 332 (0.31) 731 (0.30)  1,406 (0.33) 379 (0.30) 1,027 (0.34) 
Blood transfusion 258 (0.07) 106 (0.10) 152 (0.06)  192 (0.05) 58 (0.05) 134 (0.04) 
Anaemia 3,224 (0.91) 1,043 (0.98) 2,181 (0.88)  3,614 (0.85) 1,115 (0.87) 2,499 (0.84) 
Respiratory tract 
infection 
2,089 (0.60) 594 (0.56) 1,495 (0.61)  2,316 (0.54) 615 (0.48) 1,701 (0.57) 
Myocardial 
infarction 
460 (0.13) 139 (0.13) 321 (0.13)  572 (0.13) 162 (0.13) 410 (0.14) 
Stroke 368 (0.10) 111 (0.10) 257 (0.10)  481 (0.11) 146 (0.11) 335 (0.11) 
Major haemorrhage 478 (0.14) 145 (0.14) 333 (0.14)  643 (0.15) 207 (0.16) 436 (0.15) 
Wound disruption 546 (0.15) 164 (0.15) 382 (0.15)  1,187 (0.28) 377 (0.29) 810 (0.27) 




































DVT = deep vein thrombosis; IQR = interquartile range; OHS = Oxford Hip Score; OKS = Oxford Knee 
Score; PE = pulmonary embolism; SD = standard deviation; THR = total hip replacement; TKR = total knee 
replacement; VTE = venous thromboembolism. 
Values in brackets are percentages unless otherwise indicated.  
* Missing data for stated number of hips: EQ5D (n=170,324); OHS (n=169,851) 
* Missing data for stated number of knees: EQ5D (n=205,848); OKS (n=205,754)
 




THR adjustment for all variables 
excluding BMI (n=342,268) 
TKR adjustment for all variables 
excluding BMI (n=422,205) 
Length of stay Coefficient = -0.49 (-0.51 to -0.47) 
p<0.001 
Based on 342,246 hips 
Coefficient = -0.47 (-0.49 to -0.45) 
p<0.001 
Based on 422,179 knees 
Readmissions 
within 90 days 
OR = 0.93 (0.90-0.96) 
p<0.001 
OR = 0.91 (0.89-0.93) 
p<0.001 
Any complication 
within 90 days 
OR = 0.88 (0.85-0.91) 
p<0.001 
OR = 0.90 (0.87-0.93) 
p<0.001 
Revision at 90 
days 
OR = 1.01 (0.88-1.17) 
p=0.849 
OR = 0.99 (0.79-1.23) 
p=0.899 
Reoperations 
within 90 days 
OR = 0.86 (0.73-1.01) 
p=0.062 
OR = 0.79 (0.68-0.92) 
p=0.002 
Mortality at 90 
days 
OR = 0.91 (0.77-1.08) 
p=0.300 




within 90 days 
  
VTE  
(DVT &/or PE) 
OR = 0.85 (0.77-0.93) 
p=0.001 
OR = 0.96 (0.89-1.05) 
p=0.370 
DVT only OR = 0.93 (0.82-1.06) 
p=0.257 
OR = 0.98 (0.88-1.10) 
p=0.760 





OR = 0.85 (0.77-0.94) 
p=0.003 




OR = 0.87 (0.80-0.95) 
p=0.001 
OR = 0.84 (0.78-0.89) 
p<0.001 
Acute renal failure OR = 0.78 (0.68-0.89) 
p<0.001 
OR = 0.93 (0.82-1.04) 
p=0.208 
Blood transfusion OR = 0.62 (0.48-0.80) 
p<0.001 
OR = 0.96 (0.70-1.31) 
p=0.780 
Anaemia OR = 0.85 (0.79-0.92) 
p<0.001 




OR = 0.99 (0.90-1.09) 
p=0.808 




OR = 0.90 (0.73-1.10) 
p=0.293 
OR = 0.93 (0.77-1.11) 
p=0.409 
Stroke OR = 0.92 (0.74-1.16) 
p=0.500 
OR = 0.88 (0.72-1.07) 
p=0.203 
Major haemorrhage OR = 0.94 (0.77-1.15) 
p=0.531 
OR = 0.86 (0.73-1.02) 
p=0.075 
Wound disruption OR = 0.94 (0.78-1.14) 
p=0.550 
OR = 0.91 (0.80-1.03) 
p=0.124 
EQ5D at 6 months  
 
Coefficient = 0.021 (0.018 to 0.023) 
p<0.001 
Based on 170,173 hips 
Coefficient = 0.019 (0.017 to 0.022) 
p<0.001 
Based on 208,894 knees 
OHS or OKS at  
6 months 
Coefficient = 0.79 (0.70 to 0.88) Coefficient = 0.80 (0.71 to 0.88) 
 
 p<0.001 
Based on 176,776 hips 
p<0.001 
Based on 216,474 knees 
 
BMI = body mass index; DVT = deep vein thrombosis; OHS = Oxford Hip Score; OKS = Oxford Knee 
Score; PE = pulmonary VTE = venous thromboembolism 
Numbers in brackets represent the 95% confidence intervals. 
Odds ratios below 1 represent a reduced risk of the specified outcome in the regional anaesthetic group. 
Statistically significant p-values (p<0.05) are in bold 
 
 
Appendix 1 Codes for outcomes of interest 
Deep vein thrombosis (ICD 10) 
I80.1 Phlebitis and thrombophlebitis of femoral vein 
I80.2 Phlebitis and thrombophlebitis of other deep vessels of lower extremities 
I80.3 Phlebitis and thrombophlebitis of lower extremities, unspecified 
 
Pulmonary embolism (ICD 10) 
I26.0 Pulmonary embolism with mention of acute cor pulmonale 
I26.9 Pulmonary embolism without mention of acute cor pulmonale 
 
Reoperation hip (OPCS4) 
W801 Z756 Open debridement and irrigation of joint - Acetabulum 
W801 Z761 Open debridement and irrigation of joint - Head of femur 
W801 Z843 Open debridement and irrigation of joint - Hip joint 
W801 Z902 Open debridement and irrigation of joint - Hip NEC 
W802 Z756 Open debridement of joint NEC - Acetabulum 
W802 Z761 Open debridement of joint NEC - Head of femur 
W802 Z843 Open debridement of joint NEC - Hip joint 
W802 Z902 Open debridement of joint NEC - Hip NEC 
W803 Z756 Open irrigation of joint NEC - Acetabulum 
W803 Z761 Open irrigation of joint NEC - Head of femur 
W803 Z843 Open irrigation of joint NEC - Hip joint 
W803 Z902 Open irrigation of joint NEC - Hip NEC 
W808 Z756 Other specified debridement and irrigation of joint - Acetabulum 
W808 Z761 Other specified debridement and irrigation of joint - Head of femur 
W808 Z843 Other specified debridement and irrigation of joint - Hip joint 
W808 Z902 Other specified debridement and irrigation of joint - Hip NEC 
W809 Z756 Unspecified debridement and irrigation of joint - Acetabulum 
W809 Z761 Unspecified debridement and irrigation of joint - Head of femur 
W809 Z843 Unspecified debridement and irrigation of joint - Hip joint 
W809 Z902 Unspecified debridement and irrigation of joint - Hip NEC 
 
Reoperation knee (OPCS4) 
W852  Endoscopic irrigation of knee joint 
W801 Z765 Open debridement and irrigation of joint - Lower end of femur NEC 
W801 Z774 Open debridement and irrigation of joint - Upper end of tibia NEC 
W801 Z787 Open debridement and irrigation of joint - Patella 
W801 Z844 Open debridement and irrigation of joint - Patellofemoral joint 
W801 Z845 Open debridement and irrigation of joint - Tibiofemoral joint 
W801 Z846 Open debridement and irrigation of joint - Knee joint 
W802 Z765 Open debridement of joint NEC - Lower end of femur NEC 
W802 Z774 Open debridement of joint NEC - Upper end of tibia NEC 
W802 Z787 Open debridement of joint NEC - Patella 
W802 Z844 Open debridement of joint NEC - Patellofemoral joint 
W802 Z845 Open debridement of joint NEC - Tibiofemoral joint 
W802 Z846 Open debridement of joint NEC - Knee joint 
W803 Z765 Open irrigation of joint NEC - Lower end of femur NEC 
W803 Z744 Open irrigation of joint NEC - Upper end of tibia NEC 
W803 Z787 Open irrigation of joint NEC - Patella 
Appendix
 
W803 Z844 Open irrigation of joint NEC - Patellofemoral joint 
W803 Z845 Open irrigation of joint NEC - Tibiofemoral joint 
W803 Z846 Open irrigation of joint NEC - Knee joint 
W808 Z765 Other specified debridement and irrigation of joint - Lower end of femur NEC 
W808 Z774 Other specified debridement and irrigation of joint - Upper end of tibia NEC 
W808 Z787 Other specified debridement and irrigation of joint - Patella 
W808 Z844 Other specified debridement and irrigation of joint - Patellofemoral joint 
W808 Z845 Other specified debridement and irrigation of joint - Tibiofemoral joint 
W808 Z846 Other specified debridement and irrigation of joint - Knee joint 
W809 Z765 Unspecified debridement and irrigation of joint - Lower end of femur NEC 
W809 Z774 Unspecified debridement and irrigation of joint - Upper end of tibia NEC 
W809 Z787 Unspecified debridement and irrigation of joint - Patella 
W809 Z844 Unspecified debridement and irrigation of joint - Patellofemoral joint 
W809 Z845 Unspecified debridement and irrigation of joint - Tibiofemoral joint 
W809 Z846 Unspecified debridement and irrigation of joint - Knee joint 
 
Blood transfusion (ICD 10 and OPCS 4) 
X33.2 Intravenous blood transfusion of packed cells 
X33.3 Intravenous blood transfusion of platelets 
X33.8 Other specified other blood transfusion 
X33.9 Unspecified other blood transfusion 
X33.1 Intra-arterial blood transfusion 
X33.7 Autologous transfusion of red blood cells 
 
X331  Intra-arterial blood transfusion 
X332  Intravenous blood transfusion of packed cells 
X333  Intravenous blood transfusion of platelets 
X337  Autologous transfusion of red blood cells 
X338  Other specified blood transfusion 
X339  Other unspecified blood transfusion 
X341  Transfusion of coagluation factor 
X342  Transfusion of plasma NEC 
X343  Transfusion of serum NEC 
X344  Transfusion of blood expander 
 
Major bleeding (ICD 10) 
K25.0 Gastric ulcer : acute with haemorrhage† 
K25.1 Gastric ulcer : acute with perforation 
K25.2 Gastric ulcer : acute with both haemorrhage and perforation 
K25.3 Gastric ulcer : acute without haemorrhage or perforation 
K25.4 Gastric ulcer : chronic or unspecified with haemorrhage 
K25.5 Gastric ulcer : chronic or unspecified with perforation 
K25.6 Gastric ulcer : chronic or unspecified with both haemorrhage and perforation 
K25.7 Gastric ulcer : chronic without haemorrhage or perforation 
K25.9 Gastric ulcer : unspecified as acute or chronic, without haemorrhage or perforation 
K26.0 Duodenal ulcer : acute with haemorrhage 
K26.1 Duodenal ulcer : acute with perforation 
K26.2 Duodenal ulcer : acute with both haemorrhage and perforation 
K26.3 Duodenal ulcer : acute without haemorrhage or perforation 
K26.4 Duodenal ulcer : chronic or unspecified with haemorrhage 
 
K26.5 Duodenal ulcer : chronic or unspecified with perforation 
K26.6 Duodenal ulcer : chronic or unspecified with both haemorrhage and perforation 
K26.7 Duodenal ulcer : chronic without haemorrhage or perforation 
K26.9 Duodenal ulcer : unspecified as acute or chronic, without haemorrhage or perforation 
K27.0 Peptic ulcer, site unspecified : acute with haemorrhage 
K27.1 Peptic ulcer, site unspecified : acute with perforation 
K27.2 Peptic ulcer, site unspecified : acute with both haemorrhage and perforation 
K27.3 Peptic ulcer, site unspecified : acute without haemorrhage or perforation 
K27.4 Peptic ulcer, site unspecified : chronic or unspecified with haemorrhage 
K27.5 Peptic ulcer, site unspecified : chronic or unspecified with perforation 
K27.6 Peptic ulcer, site unspecified : chronic or unspecified with both haemorrhage and perforation 
K27.7 Peptic ulcer, site unspecified : chronic without haemorrhage or perforation 
K27.9 Peptic ulcer, site unspecified : unspecified as acute or chronic, without haemorrhage or perforation 
K28.0 Gastrojejunal ulcer : acute with haemorrhage 
K28.1 Gastrojejunal ulcer : acute with perforation 
K28.2 Gastrojejunal ulcer : acute with both haemorrhage and perforation 
K28.3 Gastrojejunal ulcer : acute without haemorrhage or perforation 
K28.4 Gastrojejunal ulcer : chronic or unspecified with haemorrhage 
K28.5 Gastrojejunal ulcer : chronic or unspecified with perforation 
K28.6 Gastrojejunal ulcer : chronic or unspecified with both haemorrhage and perforation 
K28.7 Gastrojejunal ulcer : chronic without haemorrhage or perforation 
K28.9 Gastrojejunal ulcer : unspecified as acute or chronic, without haemorrhage or perforation 
 
I60.X Subarachnoid haemorrhage 
I61.0 Intracerebral haemorrhage in hemisphere, subcortical 
I61.1 Intracerebral haemorrhage in hemisphere, cortical 
I61.2 Intracerebral haemorrhage in hemisphere, unspecified 
I61.3 Intracerebral haemorrhage in brain stem 
I61.4 Intracerebral haemorrhage in cerebellum 
I61.5 Intracerebral haemorrhage, intraventricular 
I61.6 Intracerebral haemorrhage, multiple localized 
I61.8 Other intracerebral haemorrhage 
I61.9 Intracerebral haemorrhage, unspecified 
 
Anaemia (ICD 10) 
D46.0 Refractory anaemia without ring sideroblasts, so stated 
D46.1 Refractory anaemia with ring sideroblasts 
D46.2 Refractory anaemia with excess of blasts [RAEB] 
D46.4 Refractory anaemia, unspecified 
D46.5 Refractory anaemia with multi-lineage dysplasia 
D46.7 Other myelodysplastic syndromes 
D46.9 Myelodysplastic syndrome, unspecified 
D50.0 Iron deficiency anaemia secondary to blood loss (chronic) 
D50.8 Other iron deficiency anaemias 
D50.9 Iron deficiency anaemia, unspecified 
D51.0 Vitamin B12 deficiency anaemia due to intrinsic factor deficiency 
D51.1 Vitamin B12 deficiency anaemia due to selective vitamin B12 malabsorption with proteinuria 
D51.2 Transcobalamin II deficiency 
D51.3 Other dietary vitamin B12 deficiency anaemia 
D51.8 Other vitamin B12 deficiency anaemias 
 
D51.9 Vitamin B12 deficiency anaemia, unspecified 
D52.0 Dietary folate deficiency anaemia 
D52.1 Drug-induced folate deficiency anaemia 
D52.8 Other folate deficiency anaemias 
D52.9 Folate deficiency anaemia, unspecified 
D53.0 Protein deficiency anaemia 
D53.1 Other megaloblastic anaemias, not elsewhere classified 
D53.2 Scorbutic anaemia 
D53.8 Other specified nutritional anaemias 
D53.9 Nutritional anaemia, unspecified 
D59.0 Drug-induced autoimmune haemolytic anaemia 
D59.1 Other autoimmune haemolytic anaemias 
D59.2 Drug-induced nonautoimmune haemolytic anaemia 
D59.3 Haemolytic-uraemic syndrome 
D59.4 Other nonautoimmune haemolytic anaemias 
D59.6 Haemoglobinuria due to haemolysis from other external causes 
D59.8 Other acquired haemolytic anaemias 
D59.9 Acquired haemolytic anaemia, unspecified 
D61.0 Constitutional aplastic anaemia 
D61.1 Drug-induced aplastic anaemia 
D61.2 Aplastic anaemia due to other external agents 
D61.3 Idiopathic aplastic anaemia 
D61.8 Other specified aplastic anaemias 
D61.9 Aplastic anaemia, unspecified 
D62 Acute posthaemorrhagic anaemia 
D63.0 Anaemia in neoplastic disease (C00-D48)  
D63.8 Anaemia in other chronic diseases classified elsewhere 
D64.1 Secondary sideroblastic anaemia due to disease 
D64.2 Secondary sideroblastic anaemia due to drugs and toxins 
D64.3 Other sideroblastic anaemias 
D64.8 Other specified anaemias 
D64.9 Anaemia, unspecified 
O99.0 Anaemia complicating pregnancy, childbirth and the puerperium 
P61.2 Anaemia of prematurity 
P61.4 Other congenital anaemias, not elsewhere classified 
 
Wound disruption and surgical site infection (ICD 10) 
T84.5 Infection and inflammatory reaction due to internal joint prosthesis 
T81.3 Disruption of operation wound, not elsewhere classified 
T81.4 Infection following a procedure, not elsewhere classified 
 
Myocardial infarction (ICD 10) 
I21.0 Acute transmural myocardial infarction of anterior wall 
I21.1 Acute transmural myocardial infarction of inferior wall 
I21.2 Acute transmural myocardial infarction of other sites 
I21.3 Acute transmural myocardial infarction of unspecified site 
I21.4 Acute subendocardial myocardial infarction 
I21.9 Acute myocardial infarction, unspecified 
I22.0 Subsequent myocardial infarction of anterior wall 
I22.1 Subsequent myocardial infarction of inferior wall 
 
I22.8 Subsequent myocardial infarction of other sites 
I22.9 Subsequent myocardial infarction of unspecified site 
 
Acute renal failure (ICD 10) 
N17.0  Acute renal failure with tubular necrosis 
N17.1  Acute renal failure with acute cortical necrosis 
N17.2  Acute renal failure with medullary necrosis 
N17.8  Other acute renal failure 
N17.9  Acute renal failure, unspecified 
 
Urinary tract infection (ICD 10) 
N30.0  Acute cystitis. Excluding irradiation cystitis and trigonitis 
N39.0  Urinary tract infection, site not specified 
Respiratory tract infection (ICD 10) 
J12.X  Viral pneumonia, not elsewhere classified: bronchopneumonia due to viruses other than influenza 
viruses 
J13  Pneumonia due to Streptococcus pneumonia 
J14  Pneumonia due to Haemophilus influenza 
J15.X  Bacterial pneumonia, not elsewhere classified: bronchopneumonia due to bacteria other than S. 
pneumoniae and H. influenza 
J18.0  Bronchopneumonia, unspecified. Excluding bronchiolitis 
J18.1  Lobar pneumonia, unspecified 
J18.2  Hypostatic pneumonia, unspecified 
J18.8  Other pneumonia, organism unspecified 
J18.9  Pneumonia, Unspecified 
J22  Unspecified acute lower respiratory infection 
J44.0  Chronic obstructive pulmonary disease with acute lower respiratory infection. Excluding with 
influenza 
J44.1  Chronic obstructive pulmonary disease with acute exacerbation, unspecified 
J69.0  Pneumonitis due to food and vomit. Excluding Mendelson syndrome 
J69.1  Pneumonitis due to oils and essences 
J69.8  Pneumonitis due to other solids and liquids. Pneumonitis due to aspiration of blood 
J85.1  Abscess of lung with pneumonia. Excluding with pneumonia due to specified organism 
 
Stroke (ICD 10) 
I60.X  Subarachnoid haemorrhage 
I61.0  Intracerebral haemorrhage in hemisphere, subcortical 
I61.1  Intracerebral haemorrhage in hemisphere, cortical 
I61.2  Intracerebral haemorrhage in hemisphere, unspecified 
I61.3  Intracerebral haemorrhage in brain stem 
I61.4  Intracerebral haemorrhage in cerebellum 
I61.5  Intracerebral haemorrhage, intraventricular 
I61.6  Intracerebral haemorrhage, multiple localized 
I61.8  Other intracerebral haemorrhage 
I61.9  Intracerebral haemorrhage, unspecified 
I63.0  Cerebral infarction due to thrombosis of precerebral arteries 
I63.1  Cerebral infarction due to embolism of precerebral arteries 
I63.2  Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries 
I63.3  Cerebral infarction due to thrombosis of cerebral arteries 
 
I63.4  Cerebral infarction due to embolism of cerebral arteries 
I63.5  Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries 
I63.6  Cerebral infarction due to cerebral venous thrombosis, nonpyogenic 
I63.8  Other cerebral infarction 
I63.9  Cerebral infarction, unspecified 
I64.X  Stroke, not specified as haemorrhage or infarction 
 
 
Appendix 2 Sensitivity analysis for total hip and knee replacements: univariable regression models and 














for all variables* 
including BMI 
(n=304,538) 
Length of stay Coefficient = -0.56 
(-0.59 to -0.54) 
p<0.001 
Based on 353,365 
hips 
Coefficient = -0.39 
(-0.42 to -0.36) 
p<0.001 
Based on 249,832 
hips 
Coefficient = -0.57 
(-0.59 to -0.55) 
p<0.001 
Based on 426,078 
knees 
Coefficient = -0.37 
(-0.40 to -0.34) 
p<0.001 
Based on 304,520 
knees 
Readmissions 
within 90 days 
OR = 0.95  
(0.93-0.97) 
p<0.001 
OR = 0.93 
(0.90-0.96) 
p<0.001 
OR = 0.93  
(0.91-0.95) 
p<0.001 




within 90 days 
OR = 0.90  
(0.87-0.94) 
p<0.001 
OR = 0.88 
(0.84-0.92) 
p<0.001 
OR = 0.94  
(0.91-0.97) 
p<0.001 
OR = 0.90  
(0.87-0.94) 
p<0.001 
Revision at 90 
days 
OR = 0.91  
(0.81-1.02) 
p=0.091 
OR = 1.01 
(0.88-1.17) 
p=0.849 
OR = 1.07  
(0.86-1.33) 
p=0.554 




within 90 days 
OR = 0.89  
(0.76-1.04) 
p=0.147 
OR = 0.82 
(0.68-0.99) 
p=0.042 
OR = 0.81  
(0.70-0.94) 
p=0.005 
OR = 0.73 
(0.61-0.87) 
p<0.001 
Mortality at 90 
days 
OR = 1.01  
(0.88-1.15) 
OR = 0.91 
(0.77-1.08) 
OR = 1.11  
(0.94-1.31) 
OR = 1.09 
(0.88-1.35) 
 
p=0.911 p=0.300 p=0.237 p=0.449 
Specific 
complications 
within 90 days 
    
VTE  
(DVT &/or PE) 
OR = 0.80  
(0.73-0.87) 
p<0.001 
OR = 0.84 
(0.75-0.94) 
p=0.002 
OR = 0.93  
(0.86-1.01) 
p=0.078 
OR = 0.97 
(0.87-1.07) 
p=0.508 
DVT only OR = 0.82  
(0.73-0.93) 
p=0.002 
OR = 0.90 
(0.76-1.05) 
p=0.180 
OR = 0.93  
(0.83-1.04) 
p=0.179 
OR = 1.02 
(0.89-1.18) 
p=0.750 
PE only OR = 0.77  
(0.68-0.88) 
p<0.001 
OR = 0.78 
(0.66-0.91) 
p=0.002 
OR = 0.92  
(0.82-1.03) 
p=0.155 





OR = 0.93  
(0.84-1.03) 
p=0.159 
OR = 0.88 
(0.77-1.00) 
p=0.052 
OR = 0.98  
(0.89-1.08) 
p=0.679 





OR = 0.86  
(0.79-0.93) 
p<0.001 
OR = 0.82 
(0.74-0.90) 
p<0.001 
OR = 0.82  
(0.77-0.87) 
p<0.001 
OR = 0.83 
(0.77-0.90) 
p<0.001 
Acute renal failure OR = 0.95  
(0.84-1.09) 
p=0.470 
OR = 0.85 
(0.72-0.99) 
p=0.045 
OR = 1.17  
(1.04-1.31) 
p=0.011 
OR = 0.95 
(0.82-1.10) 
p=0.495 
Blood transfusion OR = 0.62  
(0.48-0.80) 
p<0.001 
OR = 0.57 
(0.42-0.77) 
p<0.001 
OR = 0.99  
(0.73-1.35) 
p=0.964 




Anaemia OR = 0.90  
(0.84-0.97) 
p=0.008 
OR = 0.84 
(0.77-0.92) 
p<0.001 
OR = 0.96  
(0.90-1.03) 
p=0.297 





OR = 1.09  
(0.99-1.20) 
p=0.075 
OR = 0.99 
(0.88-1.11) 
p=0.861 
OR = 1.19  
(1.08-1.31) 
p<0.001 





OR = 1.00  
(0.82-1.22) 
p=1.00 
OR = 0.92 
(0.72-1.18) 
p=0.508 
OR = 1.09 
(0.91-1.31) 
p=0.364 
OR = 0.79 
(0.63-0.97) 
p=0.028 
Stroke OR = 1.00  
(0.80-1.25) 
p=0.982 
OR = 1.01 
(0.76-1.33) 
p=0.970 
OR = 0.99  
(0.81-1.20) 
p=0.889 
OR = 0.89 
(0.70-1.14) 
p=0.366 
Major haemorrhage OR = 0.99  
(0.82-1.21) 
p=0.955 
OR = 1.04 
(0.82-1.33) 
p=0.738 
OR = 0.91  
(0.77-1.07) 
p=0.238 
OR = 0.87 
(0.71-1.07) 
p=0.192 
Wound disruption OR = 1.01  
(0.84-1.21) 
p=0.927 
OR = 1.01 
(0.81-1.27) 
p=0.906 
OR = 0.92  
(0.82-1.04) 
p=0.201 
OR = 0.87 
(0.75-1.01) 
p=0.060 
EQ5D at 6 months  
 
Coefficient = 0.024 
(0.021 to 0.026) 
p<0.001 
Based on 175,224 
hips 
Coefficient = 0.023 
(0.020 to 0.026) 
p<0.001 
Based on 127,258 
hips 
Coefficient = 0.025 
(0.023 to 0.027) 
p<0.001 
Based on 210,816 
knees 
Coefficient = 0.018 
(0.016 to 0.021) 
p<0.001 
Based on 154,704 
knees 
OHS or OKS  
at 6 months 
 
Coefficient = 0.89 
(0.80 to 0.98) 
Coefficient = 0.85 
(0.75 to 0.96) 
Coefficient = 1.02 
(0.93 to 1.10) 
Coefficient = 0.80 
(0.70 to 0.90) 
 
p<0.001 
Based on 182,031 
hips 
p<0.001 
Based on 132,167 
hips 
p<0.001 
Based on 218,558 
knees 
p<0.001 
Based on 160,333 
knees 
 
BMI = body mass index; DVT = deep vein thrombosis; OHS = Oxford Hip Score; OKS = Oxford Knee 
Score; PE = pulmonary VTE = venous thromboembolism 
Numbers in brackets represent the 95% confidence intervals. 
Odds ratios below 1 represent a reduced risk of the specified outcome in the regional anaesthetic group. 
Statistically significant p-values (p<0.05) are in bold 
 
Appendix 3 Sensitivity analysis for total hip and knee replacements to assess the effect of using a nerve 
block on outcomes: multivariable models adjusted for all variables excluding body mass index 
Outcome of 
interest 
THR: GA alone 
(reference group) 
vs. GA with nerve 
block 
(n=102,206) 
THR: SA alone 
(reference group) 
vs. SA with nerve 
block 
(n=246,605) 
TKR: GA alone 
(reference group) 
vs. GA with nerve 
block 
(n=124,523) 
TKR: SA alone  
(reference group) 
vs. SA with nerve 
block 
(n=298,015) 
Length of stay Coefficient = -0.03 
(-0.09 to 0.04) 
p=0.375 
Based on 97,498 
hips 
Coefficient = -0.05 
(-0.11 to 0.004) 
p=0.071 
Based on 240,365 
hips 
Coefficient = 0.03 
(-0.02 to 0.07) 
p=0.299 
Based on 122,658 
knees 
Coefficient = 0.12 
(0.08 to 0.15) 
p<0.001 
Based on 296,002 
knees 
Readmissions 
within 90 days 
OR = 0.92  
(0.87-0.97) 
p=0.004 
OR = 0.97 
(0.91-1.03) 
p=0.269 
OR = 0.95  
(0.92-0.99) 
p=0.013 




within 90 days 
OR = 0.92  
(0.84-1.01) 
p=0.068 
OR = 0.98 
(0.89-1.07) 
p=0.624 
OR = 0.94  
(0.89-1.01) 
p=0.073 
OR = 1.04  
(0.98-1.10) 
p=0.187 
Revision at 90 
days 
OR = 1.03  
(0.78-1.36) 
p=0.841 
OR = 0.97 
(0.71-1.32) 
p=0.827 
OR = 1.08  
(0.69-1.70) 
p=0.739 




within 90 days 
OR = 1.09  
(0.76-1.56) 
p=0.642 
OR = 1.05 
(0.70-1.57) 
p=0.826 
OR = 0.99  
(0.75-1.31) 
p=0.930 
OR = 0.94 
(0.71-1.25) 
p=0.686 












within 90 days 
    
VTE  
(DVT &/or PE) 
OR = 0.82  
(0.65-1.03) 
p=0.081 
OR = 0.87 
(0.67-1.12) 
p=0.284 
OR = 1.04  
(0.89-1.22) 
p=0.610 
OR = 1.01 
(0.88-1.16) 
p=0.889 
DVT only OR = 0.84  
(0.62-1.15) 
p=0.282 
OR = 0.77 
(0.54-1.11) 
p=0.161 
OR = 0.94  
(0.75-1.16) 
p=0.561 
OR = 1.00 
(0.82-1.22) 
p=0.998 
PE only OR = 0.84 
(0.61-1.15) 
p=0.280 
OR = 1.04 
(0.73-1.46) 
p=0.839 
OR = 1.12  
(0.90-1.39) 
p=0.313 





OR = 1.03  
(0.80-1.31) 
p=0.826 
OR = 0.98 
(0.75-1.29) 
p=0.912 
OR = 1.10  
(0.91-1.32) 
p=0.347 





OR = 0.87  
(0.71-1.07) 
p=0.186 
OR = 1.01 
(0.82-1.25) 
p=0.897 
OR = 0.80  
(0.70-0.90) 
p<0.001 
OR = 0.93 
(0.82-1.04) 
p=0.209 
Acute renal failure OR = 1.15  
(0.84-1.58) 
p=0.384 
OR = 0.98 
(0.69-1.38) 
p=0.895 
OR = 0.77  
(0.59-1.01) 
p=0.051 
OR = 0.93 
(0.75-1.14) 
p=0.464 
Blood transfusion OR = 0.58  
(0.31-1.10) 
OR = 1.35 
(0.73-2.52) 
OR = 0.79  
(0.42-1.48) 
OR = 1.01 
(0.60-1.71) 
 
p=0.098 p=0.338 p=0.463 p=0.972 
Anaemia OR = 1.05  
(0.88-1.24) 
p=0.611 
OR = 0.93 
(0.76-1.13) 
p=0.477 
OR = 1.04  
(0.91-1.20) 
p=0.569 





OR = 0.97  
(0.76-1.23) 
p=0.777 
OR = 0.88 
(0.69-1.12) 
p=0.303 
OR = 0.91  
(0.75-1.11) 
p=0.352 





OR = 0.73  
(0.42-1.26) 
p=0.254 
OR = 1.17 
(0.72-1.89) 
p=0.523 
OR = 0.86 
(0.59-1.26) 
p=0.441 
OR = 1.11 
(0.82-1.50) 
p=0.495 
Stroke OR = 0.71  
(0.39-1.31) 
p=0.278 
OR = 1.12 
(0.66-1.89) 
p=0.684 
OR = 0.94  
(0.63-1.39) 
p=0.745 
OR = 0.93 
(0.65-1.31) 
p=0.669 
Major haemorrhage OR = 0.69  
(0.41-1.17) 
p=0.169 
OR = 1.24 
(0.80-1.92) 
p=0.340 
OR = 0.94  
(0.68-1.30) 
p=0.711 
OR = 0.86 
(0.63-1.18) 
p=0.357 
Wound disruption OR = 0.90  
(0.57-1.41) 
p=0.645 
OR = 0.80 
(0.48-1.32) 
p=0.378 
OR = 1.00  
(0.78-1.27) 
p=0.987 
OR = 1.04 
(0.84-1.28) 
p=0.745 
EQ5D at 6 months  
 
Coefficient =  
-0.002 
(-0.01 to 0.004) 
p=0.567 
Based on 47,152 
hips 
Coefficient = 0.001 
(-0.005 to 0.007) 
 
p=0.804 
Based on 121,120 
hips 
Coefficient = 0.010 
(0.002 to 0.012) 
 
p=0.004 
Based on 58,837 
knees 
Coefficient =  
-0.005 
(-0.01 to -0.001) 
p=0.022 
Based on 148,595 
knees 
 
OHS or OKS  
at 6 months 
 
Coefficient = -0.11 
(-0.33 to 0.11) 
p=0.331 
Based on 49,056 
hips 
Coefficient = 0.01 
(-0.20 to 0.21) 
p=0.962 
Based on 125,755 
hips 
Coefficient = 0.49 
(-0.13 to 1.11) 
p=0.122 
Based on 47,552 
knees 
Coefficient = 0.46 
(-0.08 to 1.00) 
p=0.095 
Based on 111,098 
knees 
 
BMI = body mass index; DVT = deep vein thrombosis; GA = general anaesthesia; OHS = Oxford Hip Score; 
OKS = Oxford Knee Score; PE = pulmonary; SA = spinal anaesthesia; VTE = venous thromboembolism 
Numbers in brackets represent the 95% confidence intervals. 
Odds ratios below 1 represent a reduced risk of the specified outcome in the anaesthesia with nerve block 
group (compared with the anaesthesia alone group). 
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